Quinazolines as inhibitors of endothelin converting enzyme

Details Quinazolines as inhibitors of endothelin converting enzyme Quinazolines as inhibitors of endothelin converting enzyme

C - Chemistry, Metallurgy

07

D

C07D 401/12 (2006.01) A61K 31/505 (2006.01) A61K 31/535 (2006.01) A61K 31/54 (2006.01) A61K 31/55 (2006.01) C07D 239/86 (2006.01) C07D 239/94 (2006.01) C07D 403/12 (2006.01) C07D 405/12 (2006.01) C07D 409/12 (2006.01) C07D 413/12 (2006.01) C07D 417/12 (2006.01) C07D 453/02 (2006.01) C07D 471/08 (2006.01) C07D 491/056 (2006.01) C07D 519/00 (2006.01)

Patent

CA 2206046

Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.

Cette invention concerne de nouveaux inhibiteurs à base de quinazoline employés contre l'enzyme de conversion de l'endothéline, ainsi que des procédés de préparation et des compositions pharmaceutiques de ces produits, lesquels peuvent être utilisés dans le traitement de taux importants d'endothéline et dans les cas suivants: hypertension, infarctus et ischémie du myocarde, troubles endocrinologiques, neurologiques et du métabolisme, insuffisance cardiaque, chocs endotoxiques et hémorragiques, choc septique, hémorragie sous-arachnoïdienne, arythmies, asthme, insuffisances rénales aiguës et chroniques, néphrotoxicité due à la cyclosporine A, angine, dommages de la membrane muqueuse gastrique, maladie intestinale ischémique, cancer, hypertension pulmonaire, éclampisme, troubles athérosclérotiques, y compris la maladie de Raynaud et la resténose, ischémie et angiospasme cérébraux, diabètes.

Affiliated with

Also associated with

Rating

Quinazolines as inhibitors of endothelin converting enzyme does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinazolines as inhibitors of endothelin converting enzyme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazolines as inhibitors of endothelin converting enzyme will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1353047